25 XP   0   0   10

Corcept Therapeutics Incorporated
Buy, Hold or Sell?

Let's analyse Corcept together

PenkeI guess you are interested in Corcept Therapeutics Incorporated. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Corcept Therapeutics Incorporated. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Corcept Therapeutics Incorporated

I send you an email if I find something interesting about Corcept Therapeutics Incorporated.

Quick analysis of Corcept (30 sec.)










What can you expect buying and holding a share of Corcept? (30 sec.)

How much money do you get?

How much money do you get?
$0.08
When do you have the money?
1 year
How often do you get paid?
15.0%

What is your share worth?

Current worth
$4.53
Expected worth in 1 year
$4.76
How sure are you?
82.5%

+ What do you gain per year?

Total Gains per Share
$0.30
Return On Investment
1.2%

For what price can you sell your share?

Current Price per Share
$25.19
Expected price per share
$22.76 - $33.46
How sure are you?
50%

1. Valuation of Corcept (5 min.)




Live pricePrice per Share (EOD)

$25.19

Intrinsic Value Per Share

$-4.83 - $12.23

Total Value Per Share

$-0.30 - $16.76

2. Growth of Corcept (5 min.)




Is Corcept growing?

Current yearPrevious yearGrowGrow %
How rich?$506.7m$456.3m$23.5m4.9%

How much money is Corcept making?

Current yearPrevious yearGrowGrow %
Making money$26.5m$25.3m$1.1m4.4%
Net Profit Margin21.7%25.2%--

How much money comes from the company's main activities?

3. Financial Health of Corcept (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#109 / 1031

Most Revenue
#72 / 1031

Most Profit
#56 / 1031

Most Efficient
#79 / 1031

What can you expect buying and holding a share of Corcept? (5 min.)

Welcome investor! Corcept's management wants to use your money to grow the business. In return you get a share of Corcept.

What can you expect buying and holding a share of Corcept?

First you should know what it really means to hold a share of Corcept. And how you can make/lose money.

Speculation

The Price per Share of Corcept is $25.19. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Corcept.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Corcept, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $4.53. Based on the TTM, the Book Value Change Per Share is $0.06 per quarter. Based on the YOY, the Book Value Change Per Share is $0.31 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.02 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Corcept.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.281.1%0.240.9%0.220.9%0.220.9%0.140.6%
Usd Book Value Change Per Share0.381.5%0.060.2%0.311.2%0.120.5%0.110.4%
Usd Dividend Per Share0.010.0%0.020.1%0.030.1%0.010.0%0.010.0%
Usd Total Gains Per Share0.391.5%0.070.3%0.351.4%0.130.5%0.110.5%
Usd Price Per Share32.48-25.91-23.06-20.13-14.48-
Price to Earnings Ratio28.94-28.76-27.70-23.86--148.28-
Price-to-Total Gains Ratio83.30-51.17-69.78-56.97-99.92-
Price to Book Ratio7.16-6.06-5.90-5.39-8.06-
Price-to-Total Gains Ratio83.30-51.17-69.78-56.97-99.92-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share25.19
Number of shares39
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.020.01
Usd Book Value Change Per Share0.060.12
Usd Total Gains Per Share0.070.13
Gains per Quarter (39 shares)2.914.96
Gains per Year (39 shares)11.6419.85
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
139221810
26171433630
39262655550
412343877370
515435089190
618526210109110
721607412127130
824698613145150
927779815164170
10308611017182190

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%32.08.00.080.0%32.052.03.036.8%
Book Value Change Per Share3.01.00.075.0%9.03.00.075.0%17.03.00.085.0%33.07.00.082.5%44.039.04.050.6%
Dividend per Share4.00.00.0100.0%6.00.06.050.0%6.00.014.030.0%6.00.034.015.0%6.00.081.06.9%
Total Gains per Share3.01.00.075.0%9.03.00.075.0%17.03.00.085.0%33.07.00.082.5%44.039.04.050.6%

Fundamentals of Corcept

About Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Fundamental data was last updated by Penke on 2024-03-18 17:11:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is overpriced.

1.1. Profitability of Corcept Therapeutics Incorporated.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Corcept earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Corcept to the Biotechnology industry mean.
  • A Net Profit Margin of 23.2% means that $0.23 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Corcept Therapeutics Incorporated:

  • The MRQ is 23.2%. The company is making a huge profit. +2
  • The TTM is 21.7%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ23.2%TTM21.7%+1.4%
TTM21.7%YOY25.2%-3.5%
TTM21.7%5Y27.6%-5.9%
5Y27.6%10Y8.6%+19.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ23.2%-159.2%+182.4%
TTM21.7%-202.3%+224.0%
YOY25.2%-263.0%+288.2%
5Y27.6%-452.4%+480.0%
10Y8.6%-589.0%+597.6%
1.1.2. Return on Assets

Shows how efficient Corcept is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Corcept to the Biotechnology industry mean.
  • 5.0% Return on Assets means that Corcept generated $0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Corcept Therapeutics Incorporated:

  • The MRQ is 5.0%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 4.5%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ5.0%TTM4.5%+0.5%
TTM4.5%YOY4.9%-0.4%
TTM4.5%5Y5.3%-0.8%
5Y5.3%10Y3.5%+1.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.0%-12.5%+17.5%
TTM4.5%-12.2%+16.7%
YOY4.9%-11.2%+16.1%
5Y5.3%-13.3%+18.6%
10Y3.5%-14.6%+18.1%
1.1.3. Return on Equity

Shows how efficient Corcept is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Corcept to the Biotechnology industry mean.
  • 6.2% Return on Equity means Corcept generated $0.06 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Corcept Therapeutics Incorporated:

  • The MRQ is 6.2%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 5.6%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ6.2%TTM5.6%+0.6%
TTM5.6%YOY5.6%+0.0%
TTM5.6%5Y6.0%-0.4%
5Y6.0%10Y-4.0%+10.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.2%-16.0%+22.2%
TTM5.6%-15.8%+21.4%
YOY5.6%-13.9%+19.5%
5Y6.0%-18.2%+24.2%
10Y-4.0%-19.1%+15.1%

1.2. Operating Efficiency of Corcept Therapeutics Incorporated.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Corcept is operating .

  • Measures how much profit Corcept makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Corcept to the Biotechnology industry mean.
  • An Operating Margin of 23.4% means the company generated $0.23  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Corcept Therapeutics Incorporated:

  • The MRQ is 23.4%. The company is operating efficient. +1
  • The TTM is 21.8%. The company is operating efficient. +1
Trends
Current periodCompared to+/- 
MRQ23.4%TTM21.8%+1.6%
TTM21.8%YOY27.7%-5.9%
TTM21.8%5Y30.8%-9.1%
5Y30.8%10Y9.6%+21.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ23.4%-299.5%+322.9%
TTM21.8%-208.5%+230.3%
YOY27.7%-280.2%+307.9%
5Y30.8%-459.9%+490.7%
10Y9.6%-596.9%+606.5%
1.2.2. Operating Ratio

Measures how efficient Corcept is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.77 means that the operating costs are $0.77 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Corcept Therapeutics Incorporated:

  • The MRQ is 0.766. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.780. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.766TTM0.780-0.014
TTM0.780YOY0.720+0.061
TTM0.7805Y0.689+0.092
5Y0.68910Y0.902-0.214
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7662.817-2.051
TTM0.7803.181-2.401
YOY0.7203.609-2.889
5Y0.6895.554-4.865
10Y0.9027.396-6.494

1.3. Liquidity of Corcept Therapeutics Incorporated.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Corcept is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.39 means the company has $4.39 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Corcept Therapeutics Incorporated:

  • The MRQ is 4.389. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.381. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.389TTM8.381-3.992
TTM8.381YOY7.333+1.048
TTM8.3815Y12.983-4.602
5Y12.98310Y8.303+4.679
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.3893.987+0.402
TTM8.3814.440+3.941
YOY7.3335.569+1.764
5Y12.9836.158+6.825
10Y8.3036.492+1.811
1.3.2. Quick Ratio

Measures if Corcept is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Corcept to the Biotechnology industry mean.
  • A Quick Ratio of 6.28 means the company can pay off $6.28 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Corcept Therapeutics Incorporated:

  • The MRQ is 6.277. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 11.220. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.277TTM11.220-4.943
TTM11.220YOY12.543-1.323
TTM11.2205Y20.159-8.939
5Y20.15910Y12.351+7.808
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.2773.653+2.624
TTM11.2204.158+7.062
YOY12.5435.515+7.028
5Y20.1596.012+14.147
10Y12.3516.206+6.145

1.4. Solvency of Corcept Therapeutics Incorporated.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Corcept assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Corcept to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.18 means that Corcept assets are financed with 18.5% credit (debt) and the remaining percentage (100% - 18.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Corcept Therapeutics Incorporated:

  • The MRQ is 0.185. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.187. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.185TTM0.187-0.002
TTM0.187YOY0.122+0.064
TTM0.1875Y0.115+0.071
5Y0.11510Y0.314-0.199
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1850.336-0.151
TTM0.1870.330-0.143
YOY0.1220.267-0.145
5Y0.1150.367-0.252
10Y0.3140.378-0.064
1.4.2. Debt to Equity Ratio

Measures if Corcept is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Corcept to the Biotechnology industry mean.
  • A Debt to Equity ratio of 22.7% means that company has $0.23 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Corcept Therapeutics Incorporated:

  • The MRQ is 0.227. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.231. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.227TTM0.231-0.004
TTM0.231YOY0.140+0.091
TTM0.2315Y0.133+0.098
5Y0.13310Y0.916-0.783
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2270.376-0.149
TTM0.2310.398-0.167
YOY0.1400.334-0.194
5Y0.1330.431-0.298
10Y0.9160.476+0.440

2. Market Valuation of Corcept Therapeutics Incorporated

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Corcept generates.

  • Above 15 is considered overpriced but always compare Corcept to the Biotechnology industry mean.
  • A PE ratio of 28.94 means the investor is paying $28.94 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Corcept Therapeutics Incorporated:

  • The EOD is 22.443. Based on the earnings, the company is fair priced.
  • The MRQ is 28.938. Based on the earnings, the company is overpriced. -1
  • The TTM is 28.760. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD22.443MRQ28.938-6.495
MRQ28.938TTM28.760+0.178
TTM28.760YOY27.700+1.060
TTM28.7605Y23.862+4.897
5Y23.86210Y-148.276+172.138
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD22.443-2.697+25.140
MRQ28.938-2.422+31.360
TTM28.760-2.709+31.469
YOY27.700-4.116+31.816
5Y23.862-6.257+30.119
10Y-148.276-6.478-141.798
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Corcept Therapeutics Incorporated:

  • The EOD is 119.534. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 154.127. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 51.742. Based on how much money comes from the company's main activities, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD119.534MRQ154.127-34.593
MRQ154.127TTM51.742+102.385
TTM51.742YOY24.152+27.590
TTM51.7425Y24.286+27.456
5Y24.28610Y-6.903+31.189
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD119.534-3.344+122.878
MRQ154.127-2.939+157.066
TTM51.742-3.486+55.228
YOY24.152-5.592+29.744
5Y24.286-8.464+32.750
10Y-6.903-8.872+1.969
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Corcept is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 7.16 means the investor is paying $7.16 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Corcept Therapeutics Incorporated:

  • The EOD is 5.555. Based on the equity, the company is overpriced. -1
  • The MRQ is 7.163. Based on the equity, the company is overpriced. -1
  • The TTM is 6.056. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD5.555MRQ7.163-1.608
MRQ7.163TTM6.056+1.107
TTM6.056YOY5.895+0.161
TTM6.0565Y5.394+0.661
5Y5.39410Y8.058-2.664
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.5552.198+3.357
MRQ7.1632.042+5.121
TTM6.0562.121+3.935
YOY5.8952.907+2.988
5Y5.3943.682+1.712
10Y8.0584.114+3.944
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Corcept Therapeutics Incorporated.

3.1. Institutions holding Corcept Therapeutics Incorporated

Institutions are holding 83.535% of the shares of Corcept Therapeutics Incorporated.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc15.85020.01361640769612105497.9656
2023-12-31Vanguard Group Inc9.21350.006895375322398872.5801
2023-12-31Ingalls & Snyder LLC8.06812.26398351827116340.1395
2023-12-31Renaissance Technologies Corp6.49730.338167258711110001.678
2023-12-31Parallel Advisors, LLC3.64023.6313768245447621.2022
2023-12-31State Street Corporation3.27240.005433874652444147.7763
2023-12-31Novo A/S2.32944.83662411362-966406-28.6108
2023-12-31Dimensional Fund Advisors, Inc.2.23180.0219231029729530.128
2023-12-31Geode Capital Management, LLC1.97610.0072045646879594.493
2023-12-31BTIM Corp1.78420.45261846924198771.0879
2023-12-31Federated Hermes Inc1.63230.13631689729-1645-0.0973
2023-09-30D. E. Shaw & Co LP1.46650.0432151810736845832.0496
2023-12-31Morgan Stanley - Brokerage Accounts1.25210.00371296136710895.803
2023-12-31Arrowstreet Capital Limited Partnership1.06370.03751101103-4366-0.3949
2023-12-31Northern Trust Corp1.05440.00641091498-191805-14.9462
2023-12-31Goldman Sachs Group Inc1.02930.00311065520656945160.7893
2023-12-31Charles Schwab Investment Management Inc0.86980.0074900444391114.5408
2023-12-31Man Group PLC0.7980.074782610122035836.3781
2023-12-31Bank of New York Mellon Corp0.74650.0051772754-62073-7.4354
2023-12-31NORGES BANK0.73180.0043757490-12958-1.6819
Total 65.507521.898667811747+2089743+3.1%

3.2. Funds holding Corcept Therapeutics Incorporated

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29iShares Core S&P Small-Cap ETF5.93740.1864614624690720.1478
2024-02-29Vanguard Total Stock Mkt Idx Inv2.48810.00392575595-9022-0.3491
2024-02-29Vanguard Small Cap Index2.05320.03552125400194990.9259
2024-02-29iShares Russell 2000 ETF1.87640.07321942379-317-0.0163
2024-02-29First Trust NYSE Arca Biotech ETF1.65173.407170977500
2023-12-31Federated Hermes Kaufmann R1.54561.0656160000000
2023-12-31Federated Hermes Kaufmann Growth1.54561.0656160000000
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.28340.030613285549460.0713
2024-02-29Vanguard Small Cap Growth Index Inv1.15250.08031193030198001.6876
2024-02-29SPDR® Portfolio S&P 600 Sm Cap ETF0.78950.1878172241660.0203
2023-12-31Fidelity Small Cap Index0.77120.10279828897861.2411
2024-01-31Boston Trust Walden Small Cap0.74581.2997772050-7100-0.9112
2024-01-31Fidelity Select Biotechnology0.68810.3258712299415006.1867
2024-02-29Vanguard Tax-Managed Small Cap Adm0.68110.186470501100
2024-02-29iShares Russell 2000 Growth ETF0.67860.1454702460-817-0.1162
2024-01-31BlackRock Advantage Small Cap Core Instl0.66440.4062687815607439.6868
2024-01-31DFA US Small Cap I0.58270.086460320300
2024-02-29iShares S&P Small-Cap 600 Growth ETF0.55730.236957693800
2024-01-31Fidelity Extended Market Index0.48520.029650227347160.9478
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.47070.0274487262173003.6811
Total 26.64858.980927585802+166272+0.6%

3.3. Insider Transactions

Insiders are holding 11.412% of the shares of Corcept Therapeutics Incorporated.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-01Daniel N. Swisher, Jr.SELL220023.59
2024-02-16Joseph Douglas LyonSELL100026
2024-02-16Sean MaduckSELL2706825.97
2024-02-01Daniel N. Swisher, Jr.SELL220022
2024-01-02Daniel N. Swisher, Jr.SELL220022.11
2023-12-22William GuyerSELL1000032
2023-12-05Gary Charles RobbSELL138126.27
2023-12-04Joseph Douglas LyonSELL243226
2023-12-01Daniel N. Swisher, Jr.SELL220025.47
2023-12-01Joseph Douglas LyonSELL256826
2023-12-01Sean MaduckSELL2500025.56
2023-11-02Joseph Douglas LyonSELL397728.11
2023-11-01Daniel N. Swisher, Jr.SELL220027.96
2023-11-01Sean MaduckSELL511228.08
2023-10-10Sean MaduckSELL1847127.29
2023-10-06Joseph Douglas LyonSELL258227.24
2023-10-06Sean MaduckSELL349827.24
2023-10-02Daniel N. Swisher, Jr.SELL220027.32
2023-10-02Joseph Douglas LyonSELL241827.25
2023-10-02Sean MaduckSELL303127.24

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Corcept Therapeutics Incorporated compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.3790.055+587%0.311+22%0.117+225%0.108+250%
Book Value Per Share--4.5354.281+6%3.938+15%3.696+23%2.163+110%
Current Ratio--4.3898.381-48%7.333-40%12.983-66%8.303-47%
Debt To Asset Ratio--0.1850.187-1%0.122+51%0.115+60%0.314-41%
Debt To Equity Ratio--0.2270.231-2%0.140+62%0.133+70%0.916-75%
Dividend Per Share--0.0110.019-44%0.034-68%0.011+1%0.005+103%
Eps--0.2810.237+18%0.219+28%0.217+29%0.142+98%
Free Cash Flow Per Share--0.0530.285-81%0.259-80%0.291-82%0.179-70%
Free Cash Flow To Equity Per Share--0.060-0.055+192%0.222-73%0.087-32%0.073-18%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--12.227--------
Intrinsic Value_10Y_min---4.834--------
Intrinsic Value_1Y_max--1.179--------
Intrinsic Value_1Y_min--0.514--------
Intrinsic Value_3Y_max--3.578--------
Intrinsic Value_3Y_min--0.688--------
Intrinsic Value_5Y_max--6.019--------
Intrinsic Value_5Y_min---0.076--------
Market Cap2607593230.000-39%3629380160.0002898688853.750+25%2671894985.000+36%2404235509.750+51%1734158837.625+109%
Net Profit Margin--0.2320.217+7%0.252-8%0.276-16%0.086+170%
Operating Margin--0.2340.218+7%0.277-16%0.308-24%0.096+143%
Operating Ratio--0.7660.780-2%0.720+6%0.689+11%0.902-15%
Pb Ratio5.555-29%7.1636.056+18%5.895+21%5.394+33%8.058-11%
Pe Ratio22.443-29%28.93828.760+1%27.700+4%23.862+21%-148.276+612%
Price Per Share25.190-29%32.48025.909+25%23.063+41%20.128+61%14.483+124%
Price To Free Cash Flow Ratio119.534-29%154.12751.742+198%24.152+538%24.286+535%-6.903+104%
Price To Total Gains Ratio64.605-29%83.30251.170+63%69.780+19%56.968+46%99.921-17%
Quick Ratio--6.27711.220-44%12.543-50%20.159-69%12.351-49%
Return On Assets--0.0500.045+11%0.049+2%0.053-5%0.035+45%
Return On Equity--0.0620.056+10%0.056+10%0.060+3%-0.040+164%
Total Gains Per Share--0.3900.075+423%0.345+13%0.127+206%0.114+243%
Usd Book Value--506705000.000479895500.000+6%456335750.000+11%443000400.000+14%260695275.000+94%
Usd Book Value Change Per Share--0.3790.055+587%0.311+22%0.117+225%0.108+250%
Usd Book Value Per Share--4.5354.281+6%3.938+15%3.696+23%2.163+110%
Usd Dividend Per Share--0.0110.019-44%0.034-68%0.011+1%0.005+103%
Usd Eps--0.2810.237+18%0.219+28%0.217+29%0.142+98%
Usd Free Cash Flow--5887000.00031725000.000-81%29977500.000-80%34999700.000-83%21740925.000-73%
Usd Free Cash Flow Per Share--0.0530.285-81%0.259-80%0.291-82%0.179-70%
Usd Free Cash Flow To Equity Per Share--0.060-0.055+192%0.222-73%0.087-32%0.073-18%
Usd Market Cap2607593230.000-39%3629380160.0002898688853.750+25%2671894985.000+36%2404235509.750+51%1734158837.625+109%
Usd Price Per Share25.190-29%32.48025.909+25%23.063+41%20.128+61%14.483+124%
Usd Profit--31355000.00026535000.000+18%25354500.000+24%26013100.000+21%17378575.000+80%
Usd Revenue--135405000.000120593750.000+12%100464500.000+35%95528550.000+42%61979475.000+118%
Usd Total Gains Per Share--0.3900.075+423%0.345+13%0.127+206%0.114+243%
 EOD+4 -4MRQTTM+24 -11YOY+17 -185Y+18 -1710Y+24 -11

4.2. Fundamental Score

Let's check the fundamental score of Corcept Therapeutics Incorporated based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1522.443
Price to Book Ratio (EOD)Between0-15.555
Net Profit Margin (MRQ)Greater than00.232
Operating Margin (MRQ)Greater than00.234
Quick Ratio (MRQ)Greater than16.277
Current Ratio (MRQ)Greater than14.389
Debt to Asset Ratio (MRQ)Less than10.185
Debt to Equity Ratio (MRQ)Less than10.227
Return on Equity (MRQ)Greater than0.150.062
Return on Assets (MRQ)Greater than0.050.050
Total7/10 (70.0%)

4.3. Technical Score

Let's check the technical score of Corcept Therapeutics Incorporated based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5059.652
Ma 20Greater thanMa 5024.145
Ma 50Greater thanMa 10023.377
Ma 100Greater thanMa 20025.160
OpenGreater thanClose25.430
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets621,517
Total Liabilities114,812
Total Stockholder Equity506,705
 As reported
Total Liabilities 114,812
Total Stockholder Equity+ 506,705
Total Assets = 621,517

Assets

Total Assets621,517
Total Current Assets458,636
Long-term Assets162,881
Total Current Assets
Cash And Cash Equivalents 135,551
Short-term Investments 232,670
Net Receivables 55,123
Inventory 7,730
Other Current Assets 27,562
Total Current Assets  (as reported)458,636
Total Current Assets  (calculated)458,636
+/-0
Long-term Assets
Property Plant Equipment 315
Long Term Investments 57,176
Long-term Assets Other 14,785
Long-term Assets  (as reported)162,881
Long-term Assets  (calculated)72,276
+/- 90,605

Liabilities & Shareholders' Equity

Total Current Liabilities104,505
Long-term Liabilities10,307
Total Stockholder Equity506,705
Total Current Liabilities
Short-term Debt 151
Accounts payable 17,396
Other Current Liabilities 654
Total Current Liabilities  (as reported)104,505
Total Current Liabilities  (calculated)18,201
+/- 86,304
Long-term Liabilities
Capital Lease Obligations 151
Long-term Liabilities  (as reported)10,307
Long-term Liabilities  (calculated)151
+/- 10,156
Total Stockholder Equity
Common Stock133
Retained Earnings 402,526
Accumulated Other Comprehensive Income 609
Other Stockholders Equity 103,437
Total Stockholder Equity (as reported)506,705
Total Stockholder Equity (calculated)506,705
+/-0
Other
Capital Stock133
Cash and Short Term Investments 368,221
Common Stock Shares Outstanding 111,742
Current Deferred Revenue86,304
Liabilities and Stockholders Equity 621,517
Net Debt -135,400
Net Invested Capital 506,705
Net Working Capital 354,131
Property Plant and Equipment Gross 315
Short Long Term Debt Total 151



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312001-09-302000-12-31
> Total Assets 
1,046
27,135
21,795
0
0
0
11,781
10,283
56,124
52,489
47,772
41,929
38,135
34,321
30,156
25,602
18,170
12,646
9,902
9,902
12,930
21,104
17,744
32,437
27,843
24,699
19,775
21,169
15,610
11,620
24,511
19,216
36,097
29,700
25,104
59,837
52,720
46,379
39,833
42,887
38,618
105,524
99,166
88,141
79,687
71,057
63,077
52,831
44,390
37,159
34,630
48,224
48,355
48,377
51,937
52,912
56,838
62,930
68,753
75,339
86,537
110,672
220,537
242,976
274,382
299,751
311,694
320,212
328,679
367,022
412,312
445,494
497,823
534,125
571,731
552,398
568,480
585,399
423,756
468,123
496,364
533,255
583,430
617,848
524,625
594,022
621,517
621,517594,022524,625617,848583,430533,255496,364468,123423,756585,399568,480552,398571,731534,125497,823445,494412,312367,022328,679320,212311,694299,751274,382242,976220,537110,67286,53775,33968,75362,93056,83852,91251,93748,37748,35548,22434,63037,15944,39052,83163,07771,05779,68788,14199,166105,52438,61842,88739,83346,37952,72059,83725,10429,70036,09719,21624,51111,62015,61021,16919,77524,69927,84332,43717,74421,10412,9309,9029,90212,64618,17025,60230,15634,32138,13541,92947,77252,48956,12410,28311,78100021,79527,1351,046
   > Total Current Assets 
0
0
0
0
0
0
11,743
9,341
52,912
49,579
38,239
33,077
33,655
30,641
29,505
25,490
18,058
12,534
9,799
9,799
12,836
21,012
17,656
32,352
27,761
24,514
19,579
20,972
15,421
11,402
24,420
19,129
36,006
29,600
24,996
59,805
52,685
46,336
39,775
42,785
38,299
104,619
95,062
84,201
74,570
66,223
58,311
48,120
39,437
32,375
30,230
44,186
44,691
45,179
48,980
50,514
55,184
59,781
65,689
73,189
83,462
94,044
140,597
165,419
197,175
224,191
240,590
216,864
263,344
267,310
352,647
391,836
438,333
463,493
524,247
409,624
411,270
401,900
381,387
388,220
427,555
452,402
498,707
528,179
432,588
431,527
458,636
458,636431,527432,588528,179498,707452,402427,555388,220381,387401,900411,270409,624524,247463,493438,333391,836352,647267,310263,344216,864240,590224,191197,175165,419140,59794,04483,46273,18965,68959,78155,18450,51448,98045,17944,69144,18630,23032,37539,43748,12058,31166,22374,57084,20195,062104,61938,29942,78539,77546,33652,68559,80524,99629,60036,00619,12924,42011,40215,42120,97219,57924,51427,76132,35217,65621,01212,8369,7999,79912,53418,05825,49029,50530,64133,65533,07738,23949,57952,9129,34111,743000000
       Cash And Cash Equivalents 
1,001
0
18,402
0
0
0
10,073
8,993
35,235
22,024
5,930
3,501
2,826
1,412
3,816
2,132
3,819
3,296
8,906
8,906
11,949
18,565
11,433
31,791
26,123
16,320
14,716
19,194
14,447
10,716
23,867
18,548
35,385
29,000
24,578
59,201
52,230
45,909
39,635
42,627
34,899
101,628
93,032
81,460
72,220
63,175
54,877
43,618
33,974
26,780
24,248
37,953
37,048
36,450
40,435
40,744
41,789
47,865
51,536
57,267
67,659
76,664
104,025
140,372
31,165
33,894
206,760
49,650
225,702
44,948
315,314
349,005
58,523
30,560
476,892
52,381
95,430
94,688
335,812
61,862
381,976
50,243
436,619
465,057
172,377
111,800
135,551
135,551111,800172,377465,057436,61950,243381,97661,862335,81294,68895,43052,381476,89230,56058,523349,005315,31444,948225,70249,650206,76033,89431,165140,372104,02576,66467,65957,26751,53647,86541,78940,74440,43536,45037,04837,95324,24826,78033,97443,61854,87763,17572,22081,46093,032101,62834,89942,62739,63545,90952,23059,20124,57829,00035,38518,54823,86710,71614,44719,19414,71616,32026,12331,79111,43318,56511,9498,9068,9063,2963,8192,1323,8161,4122,8263,5015,93022,02435,2358,99310,07300018,40201,001
       Short-term Investments 
0
0
3,142
0
0
0
1,504
0
16,798
26,882
31,471
28,779
29,512
28,399
25,264
21,808
13,641
8,738
550
550
0
2,017
5,933
5,933
0
6,504
3,593
1,450
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,798
32,542
44,096
57,682
92,241
128,780
161,300
165,135
137,255
143,396
186,697
244,693
222,838
346,835
398,233
364,506
320,578
274,552
266,643
145,918
283,665
334,740
346,019
365,343
165,115
190,885
243,425
232,670
232,670243,425190,885165,115365,343346,019334,740283,665145,918266,643274,552320,578364,506398,233346,835222,838244,693186,697143,396137,255165,135161,300128,78092,24157,68244,09632,54214,79800000000000000000000000000000001,4503,5936,50405,9335,9332,01705505508,73813,64121,80825,26428,39929,51228,77931,47126,88216,79801,5040003,14200
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
355
354
557
1,143
855
1,019
1,428
1,922
2,225
2,746
3,334
4,301
4,951
5,945
6,221
6,752
9,301
8,236
9,860
9,214
9,504
11,872
28,196
17,261
28,704
19,360
17,588
19,218
19,774
22,405
19,928
26,684
22,725
21,957
26,198
22,200
27,620
26,508
27,625
27,178
28,164
29,414
45,057
46,557
46,553
48,626
55,123
55,12348,62646,55346,55745,05729,41428,16427,17827,62526,50827,62022,20026,19821,95722,72526,68419,92822,40519,77419,21817,58819,36028,70417,26128,19611,8729,5049,2149,8608,2369,3016,7526,2215,9454,9514,3013,3342,7462,2251,9221,4281,0198551,1435573543550000000000000000000000000000000000000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
56
2,437
1,837
853
1,026
694
1,025
1,096
1,127
1,072
1,080
1,207
1,310
1,451
1,604
1,682
1,912
4,094
2,327
2,329
6,708
6,299
5,508
8,376
7,786
4,947
5,362
16,242
5,000
17,868
5,462
17,405
16,147
4,927
4,817
21,157
4,948
4,669
4,994
17,950
5,079
17,415
6,046
17,031
16,565
6,915
7,513
7,730
7,7307,5136,91516,56517,0316,04617,4155,07917,9504,9944,6694,94821,1574,8174,92716,14717,4055,46217,8685,00016,2425,3624,9477,7868,3765,5086,2996,7082,3292,3274,0941,9121,6821,6041,4511,3101,2071,0801,0721,1271,0961,0256941,0268531,8372,43756000000000000000000000000000000000000000
   > Long-term Assets 
0
0
0
0
0
0
38
942
3,212
2,910
9,532
8,852
4,480
3,680
651
112
112
112
0
103
94
92
88
85
82
185
196
197
189
218
91
87
91
100
108
32
35
43
58
102
319
905
4,104
3,940
5,117
4,834
4,766
4,711
4,953
4,784
4,400
4,038
3,664
3,198
2,957
2,398
1,654
3,149
3,064
2,150
3,075
16,628
79,940
77,557
77,207
75,560
71,104
103,348
65,335
99,712
59,665
53,658
59,490
70,632
47,484
142,774
157,210
183,499
42,369
79,903
68,809
80,853
84,723
89,669
92,037
162,495
162,881
162,881162,49592,03789,66984,72380,85368,80979,90342,369183,499157,210142,77447,48470,63259,49053,65859,66599,71265,335103,34871,10475,56077,20777,55779,94016,6283,0752,1503,0643,1491,6542,3982,9573,1983,6644,0384,4004,7844,9534,7114,7664,8345,1173,9404,10490531910258433532108100918791218189197196185828588929410301121121126513,6804,4808,8529,5322,9103,21294238000000
       Property Plant Equipment 
31
39
23
0
0
0
1
0
0
0
0
0
50
55
52
49
45
42
38
38
32
28
25
22
18
15
20
17
15
12
10
7
5
4
4
4
3
3
26
30
59
105
150
154
139
184
203
285
296
273
236
230
173
143
98
93
76
145
205
302
499
553
518
577
552
540
655
2,390
1,106
1,969
3,446
3,082
4,091
4,304
2,509
3,501
2,938
2,248
514
3,542
2,264
2,508
1,143
575
648
480
315
3154806485751,1432,5082,2643,5425142,2482,9383,5012,5094,3044,0913,0823,4461,9691,1062,390655540552577518553499302205145769398143173230236273296285203184139154150105593026334445710121517201518222528323838424549525550000001000233931
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,493
1,494
1,508
15,281
15,010
0
1,481
0
28,842
24,165
35,250
39,352
41,690
4,200
15,425
36,196
81,834
101,657
133,845
112,277
22,566
11,890
4,895
4,947
0
0
59,621
57,176
57,17659,621004,9474,89511,89022,566112,277133,845101,65781,83436,19615,4254,20041,69039,35235,25024,16528,84201,481015,01015,2811,5081,4944,49300000000000000000000000000000000000000000000000000000000000
       Other Assets 
0
0
33
0
0
0
37
942
3,212
2,910
9,533
8,852
4,430
3,625
599
63
67
70
65
61
62
64
63
63
64
170
176
180
174
206
81
80
86
95
104
28
32
40
32
72
260
800
3,954
3,786
4,978
4,650
4,563
4,426
4,657
4,511
4,164
3,808
3,491
3,055
2,859
2,305
1,984
3,004
2,859
8,362
4,753
16,177
95,834
76,566
76,655
73,539
74,219
72,116
69,576
62,493
61,106
55,066
51,199
50,903
52,850
57,439
52,615
47,406
43,500
53,795
66,545
73,450
77,454
0
0
102,394
0
0102,3940077,45473,45066,54553,79543,50047,40652,61557,43952,85050,90351,19955,06661,10662,49369,57672,11674,21973,53976,65576,56695,83416,1774,7538,3622,8593,0041,9842,3052,8593,0553,4913,8084,1644,5114,6574,4264,5634,6504,9783,7863,954800260723240322810495868081206174180176170646363646261657067635993,6254,4308,8529,5332,9103,212942370003300
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
76,703
73,583
71,102
66,126
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000066,12671,10273,58376,70300000000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
1,242
1,617
2,020
0
0
0
1,538
43,774
1,401
1,634
1,824
1,261
1,513
2,701
3,563
5,234
5,204
5,668
3,542
3,542
1,442
2,682
3,010
2,323
1,929
3,295
2,868
3,287
2,139
2,358
2,419
2,143
2,859
3,000
3,860
3,196
3,856
2,713
5,026
3,570
5,816
33,873
37,389
37,138
39,316
40,284
42,060
43,460
40,938
38,476
38,018
37,652
36,829
34,900
33,439
32,744
31,178
31,683
27,374
25,759
20,392
24,370
29,569
27,749
30,873
40,206
35,812
34,457
30,626
32,646
41,130
36,005
44,125
44,445
48,393
41,596
45,805
45,170
47,950
60,312
54,038
59,891
81,588
88,264
103,011
132,343
114,812
114,812132,343103,01188,26481,58859,89154,03860,31247,95045,17045,80541,59648,39344,44544,12536,00541,13032,64630,62634,45735,81240,20630,87327,74929,56924,37020,39225,75927,37431,68331,17832,74433,43934,90036,82937,65238,01838,47640,93843,46042,06040,28439,31637,13837,38933,8735,8163,5705,0262,7133,8563,1963,8603,0002,8592,1432,4192,3582,1393,2872,8683,2951,9292,3233,0102,6821,4423,5423,5425,6685,2045,2343,5632,7011,5131,2611,8241,6341,40143,7741,5380002,0201,6171,242
   > Total Current Liabilities 
1,242
1,154
1,517
0
0
0
1,014
1,530
1,401
1,634
1,824
1,261
1,503
2,656
3,521
5,195
5,168
5,636
3,513
3,513
1,420
2,663
2,994
2,309
1,917
3,286
2,862
3,283
2,138
2,358
2,419
2,143
2,859
3,000
3,860
3,196
3,856
2,713
5,026
3,570
5,816
5,548
8,359
8,243
9,079
10,142
12,738
15,242
13,302
12,486
13,555
15,526
17,430
18,767
20,876
24,025
31,178
31,683
27,374
15,652
15,819
24,370
29,569
27,749
30,873
40,206
35,812
34,218
30,626
32,396
41,130
36,005
42,243
43,048
10,554
40,601
45,402
44,757
6,908
57,244
54,038
53,068
81,588
25,216
93,059
121,873
104,505
104,505121,87393,05925,21681,58853,06854,03857,2446,90844,75745,40240,60110,55443,04842,24336,00541,13032,39630,62634,21835,81240,20630,87327,74929,56924,37015,81915,65227,37431,68331,17824,02520,87618,76717,43015,52613,55512,48613,30215,24212,73810,1429,0798,2438,3595,5485,8163,5705,0262,7133,8563,1963,8603,0002,8592,1432,4192,3582,1383,2832,8623,2861,9172,3092,9942,6631,4203,5133,5135,6365,1685,1953,5212,6561,5031,2611,8241,6341,4011,5301,0140001,5171,1541,242
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12
12
12
13
13
13
13
14
13
12
11
10
10
10
11
9
6
4
0
0
0
0
0
0
0
0
0
2,250
2,650
3,900
3,650
4,500
5,743
6,896
7,396
8,661
9,424
10,658
12,034
13,507
14,965
16,322
22,301
18,725
14,664
10,107
4,573
0
0
0
0
0
0
1,521
1,148
770
3,461
3,112
2,019
2,034
2,050
2,067
1,559
1,046
526
2,264
2,264
1,707
1,143
575
297
225
151
1512252975751,1431,7072,2642,2645261,0461,5592,0672,0502,0342,0193,1123,4617701,1481,5210000004,57310,10714,66418,72522,30116,32214,96513,50712,03410,6589,4248,6617,3966,8965,7434,5003,6503,9002,6502,25000000000046911101010111213141313131312121200000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,424
0
0
0
14,965
0
18,557
18,725
14,664
10,107
4,573
0
0
0
0
0
0
1,521
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000001,5210000004,57310,10714,66418,72518,557014,9650009,42400000000000000000000000000000000000000000000000000
       Accounts payable 
72
240
805
0
0
0
322
936
630
980
550
285
125
833
549
1,231
1,265
2,618
916
916
306
1,666
1,115
878
1,098
1,003
1,304
1,571
670
892
1,270
1,023
1,173
1,700
817
1,865
2,291
1,066
3,611
2,084
4,235
1,574
3,804
2,263
3,033
2,337
2,381
3,666
2,595
1,960
1,886
1,036
2,360
1,740
1,325
2,082
2,081
4,309
2,290
4,253
2,082
6,226
8,579
7,850
6,365
13,922
8,266
9,330
7,026
5,937
7,537
4,976
6,304
6,510
10,554
6,969
9,216
6,558
6,908
9,269
8,246
8,178
11,976
11,216
7,976
16,710
17,396
17,39616,7107,97611,21611,9768,1788,2469,2696,9086,5589,2166,96910,5546,5106,3044,9767,5375,9377,0269,3308,26613,9226,3657,8508,5796,2262,0824,2532,2904,3092,0812,0821,3251,7402,3601,0361,8861,9602,5953,6662,3812,3373,0332,2633,8041,5744,2352,0843,6111,0662,2911,8658171,7001,1731,0231,2708926701,5711,3041,0031,0988781,1151,6663069169162,6181,2651,23154983312528555098063093632200080524072
       Other Current Liabilities 
271
914
712
0
0
0
692
594
771
654
1,275
976
1,378
1,823
295
3,952
3,891
3,005
2,584
222
1,101
983
350
1,419
228
1,297
316
1,702
1,457
1,457
224
1,116
1,686
1,300
3,043
1,331
1,565
1,647
1,415
1,486
1,555
1,703
1,889
2,004
2,359
3,250
4,589
4,651
3,267
1,815
2,212
3,777
2,999
3,441
4,428
126
6,796
332
319
11,399
13,737
18,144
20,990
19,899
24,508
26,284
27,546
450
22,452
552
30,132
27,917
28,503
34,504
34,890
31,565
33,962
37,153
40,107
45,711
43,528
43,183
68,469
13,425
74,834
94,468
654
65494,46874,83413,42568,46943,18343,52845,71140,10737,15333,96231,56534,89034,50428,50327,91730,13255222,45245027,54626,28424,50819,89920,99018,14413,73711,3993193326,7961264,4283,4412,9993,7772,2121,8153,2674,6514,5893,2502,3592,0041,8891,7031,5551,4861,4151,6471,5651,3313,0431,3001,6861,1162241,4571,4571,7023161,2972281,4193509831,1012222,5843,0053,8913,9522951,8231,3789761,275654771594692000712914271
   > Long-term Liabilities 
0
0
0
0
0
0
524
42,245
0
0
0
0
10
45
42
39
36
32
0
29
22
19
16
14
12
9
6
4
1
0
0
0
0
0
0
0
0
0
0
0
0
28,325
29,030
28,895
30,237
30,142
29,322
28,218
27,636
25,990
24,463
22,126
19,399
16,133
12,563
8,719
3,744
0
0
10,107
4,573
0
0
0
0
0
239
239
245
250
2,289
1,930
1,882
1,397
37,839
995
403
413
41,042
3,068
4,981
6,823
9,097
63,048
9,952
10,470
10,307
10,30710,4709,95263,0489,0976,8234,9813,06841,04241340399537,8391,3971,8821,9302,289250245239239000004,57310,107003,7448,71912,56316,13319,39922,12624,46325,99027,63628,21829,32230,14230,23728,89529,03028,32500000000000014691214161922290323639424510000042,245524000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
28,325
29,030
28,895
30,237
30,142
29,322
28,218
27,636
25,990
24,463
22,126
19,399
16,133
12,563
8,719
3,744
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000003,7448,71912,56316,13319,39922,12624,46325,99027,63628,21829,32230,14230,23728,89529,03028,32500000000000000000000000000000000000000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
76,703
73,583
71,102
66,126
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000066,12671,10273,58376,70300000000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
239
239
245
250
386
389
396
400
398
995
403
413
409
2,516
43,528
6,823
9,097
0
0
10,470
0
010,470009,0976,82343,5282,516409413403995398400396389386250245239239000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
0
25,518
19,775
0
0
0
10,243
-33,491
54,724
50,855
45,948
40,668
36,622
31,620
26,593
20,368
12,966
6,978
6,360
6,360
11,488
18,422
14,734
30,114
25,914
21,404
16,907
17,882
13,471
9,262
22,092
17,073
33,238
26,700
21,244
56,641
48,864
43,666
34,807
39,317
32,802
71,651
61,777
51,003
40,371
30,773
21,017
9,371
3,452
-1,317
-3,388
10,572
11,526
13,477
18,498
20,168
25,660
31,247
41,379
49,580
66,145
86,302
190,968
215,227
243,509
259,545
275,882
285,755
298,053
334,376
371,182
409,489
453,698
489,680
523,338
510,802
522,675
540,229
375,806
407,811
442,326
473,364
501,842
529,584
421,614
461,679
506,705
506,705461,679421,614529,584501,842473,364442,326407,811375,806540,229522,675510,802523,338489,680453,698409,489371,182334,376298,053285,755275,882259,545243,509215,227190,96886,30266,14549,58041,37931,24725,66020,16818,49813,47711,52610,572-3,388-1,3173,4529,37121,01730,77340,37151,00361,77771,65132,80239,31734,80743,66648,86456,64121,24426,70033,23817,07322,0929,26213,47117,88216,90721,40425,91430,11414,73418,42211,4886,3606,3606,97812,96620,36826,59331,62036,62240,66845,94850,85554,724-33,49110,24300019,77525,5180
   Retained Earnings 
0
0
0
0
0
0
-37,937
-40,488,355
-44,072
-48,161
-53,472
-58,984
-63,095
-68,318
-73,565
-80,295
-88,159
-94,562
-98,438
-98,438
-102,390
-105,818
-110,011
-113,941
-118,336
-123,901
-130,072
-135,522
-140,400
-145,068
-150,238
-156,311
-162,006
-169,100
-176,204
-183,305
-192,187
-198,622
-208,558
-219,592
-227,188
-235,482
-246,606
-258,690
-270,587
-281,493
-292,617
-306,547
-314,098
-320,105
-324,000
-328,830
-330,766
-331,367
-330,408
-330,427
-329,450
-326,865
-322,268
-317,880
-305,233
-291,476
-193,146
-175,687
-157,491
-139,744
-117,736
-99,462
-79,276
-52,936
-23,555
6,510
34,837
56,462
82,456
105,921
132,444
162,915
194,968
217,765
245,177
279,785
296,386
312,265
339,793
371,171
402,526
402,526371,171339,793312,265296,386279,785245,177217,765194,968162,915132,444105,92182,45656,46234,8376,510-23,555-52,936-79,276-99,462-117,736-139,744-157,491-175,687-193,146-291,476-305,233-317,880-322,268-326,865-329,450-330,427-330,408-331,367-330,766-328,830-324,000-320,105-314,098-306,547-292,617-281,493-270,587-258,690-246,606-235,482-227,188-219,592-208,558-198,622-192,187-183,305-176,204-169,100-162,006-156,311-150,238-145,068-140,400-135,522-130,072-123,901-118,336-113,941-110,011-105,818-102,390-98,438-98,438-94,562-88,159-80,295-73,565-68,318-63,095-58,984-53,472-48,161-44,072-40,488,355-37,937000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
-1
-43,930
-2,777
-2,418
-1,964
-1,705
-1,312
-1,112
-879
-721
-587
-469
-75
-353
-145
-132
-117
-6,113
-6,102
-6,129
-31
-31
0
0
-41
-41
0
0
-47
-47
0
0
-50
-50
-227,000
-235,000
-77
-77
0
0
-148
-148
0
0
-289
-289
0
0
-365
-365
0
0
-452
-12
-17
-14
-75
-152
-127
-77
-70
94
321
314
261
310
840
577
415
249
215
115
-227
-1,351
-2,141
-2,381
-869
-153
45
-234
609
609-23445-153-869-2,381-2,141-1,351-22711521524941557784031026131432194-70-77-127-152-75-14-17-12-45200-365-36500-289-28900-148-14800-77-77-235,000-227,000-50-5000-47-4700-41-4100-31-31-6,129-6,102-6,113-117-132-145-353-75-469-587-721-879-1,112-1,312-1,705-1,964-2,418-2,777-43,930-1000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
240,973
242,209
243,281
258,820
259,901
307,033
308,283
309,593
310,858
312,166
313,534
315,817
317,449
318,687
320,511
339,294
342,184
344,735
348,796
350,485
355,000
358,001
363,534
367,359
371,282
377,678
384,074
390,951
401,011
408,154
417,228
427,317
436,622
446,611
457,060
465,528
481,714
496,489
516,140
536,363
554,154
571,377
591,349
608,717
625,976
648,831
0
679,848
695,718
0
0
00695,718679,8480648,831625,976608,717591,349571,377554,154536,363516,140496,489481,714465,528457,060446,611436,622427,317417,228408,154401,011390,951384,074377,678371,282367,359363,534358,001355,000350,485348,796344,735342,184339,294320,511318,687317,449315,817313,534312,166310,858309,593308,283307,033259,901258,820243,281242,209240,973000000000000000000000000000000000000
   Treasury Stock000000000000000-62,979-62,704-59,732-59,732-42,312-23,657-8,90400000000000000000000000000000000000000000000000000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue482,375
Cost of Revenue-6,481
Gross Profit475,894475,894
 
Operating Income (+$)
Gross Profit475,894
Operating Expense-368,612
Operating Income107,282107,282
 
Operating Expense (+$)
Research Development184,353
Selling General Administrative184,259
Selling And Marketing Expenses0
Operating Expense368,612368,612
 
Net Interest Income (+$)
Interest Income17,275
Interest Expense-0
Other Finance Cost-0
Net Interest Income17,275
 
Pretax Income (+$)
Operating Income107,282
Net Interest Income17,275
Other Non-Operating Income Expenses0
Income Before Tax (EBT)124,55790,007
EBIT - interestExpense = 107,282
124,557
106,140
Interest Expense0
Earnings Before Interest and Taxes (EBIT)107,282124,557
Earnings Before Interest and Taxes (EBITDA)109,644
 
After tax Income (+$)
Income Before Tax124,557
Tax Provision-18,417
Net Income From Continuing Ops106,140106,140
Net Income106,140
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses375,093
Total Other Income/Expenses Net17,275-17,275
 

Technical Analysis of Corcept
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Corcept. The general trend of Corcept is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Corcept's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Corcept Therapeutics Incorporated.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 26.00 < 33.28 < 33.46.

The bearish price targets are: 25.00 > 24.61 > 22.76.

Tweet this
Corcept Therapeutics Incorporated Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Corcept Therapeutics Incorporated. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Corcept Therapeutics Incorporated Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Corcept Therapeutics Incorporated. The current macd is 0.39837307.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Corcept price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Corcept. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Corcept price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Corcept Therapeutics Incorporated Daily Moving Average Convergence/Divergence (MACD) ChartCorcept Therapeutics Incorporated Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Corcept Therapeutics Incorporated. The current adx is 12.68.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Corcept shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Corcept Therapeutics Incorporated Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Corcept Therapeutics Incorporated. The current sar is 22.15.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Corcept Therapeutics Incorporated Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Corcept Therapeutics Incorporated. The current rsi is 59.65. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending down: The RSI is trending down. -1
Corcept Therapeutics Incorporated Daily Relative Strength Index (RSI) ChartCorcept Therapeutics Incorporated Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Corcept Therapeutics Incorporated. The current phase is Overbought in neutral market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Corcept price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Corcept Therapeutics Incorporated Daily Stochastic Oscillator ChartCorcept Therapeutics Incorporated Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Corcept Therapeutics Incorporated. The current cci is 172.58.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Corcept Therapeutics Incorporated Daily Commodity Channel Index (CCI) ChartCorcept Therapeutics Incorporated Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Corcept Therapeutics Incorporated. The current cmo is 29.42.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Corcept Therapeutics Incorporated Daily Chande Momentum Oscillator (CMO) ChartCorcept Therapeutics Incorporated Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Corcept Therapeutics Incorporated. The current willr is -16.50165017.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Corcept Therapeutics Incorporated Daily Williams %R ChartCorcept Therapeutics Incorporated Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Corcept Therapeutics Incorporated.

Corcept Therapeutics Incorporated Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Corcept Therapeutics Incorporated. The current atr is 0.90481689.

Corcept Therapeutics Incorporated Daily Average True Range (ATR) ChartCorcept Therapeutics Incorporated Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Corcept Therapeutics Incorporated. The current obv is -31,427,577.

Corcept Therapeutics Incorporated Daily On-Balance Volume (OBV) ChartCorcept Therapeutics Incorporated Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Corcept Therapeutics Incorporated. The current mfi is 63.20.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Corcept Therapeutics Incorporated Daily Money Flow Index (MFI) ChartCorcept Therapeutics Incorporated Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Corcept Therapeutics Incorporated.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-08MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-27BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Corcept Therapeutics Incorporated Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Corcept Therapeutics Incorporated based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5059.652
Ma 20Greater thanMa 5024.145
Ma 50Greater thanMa 10023.377
Ma 100Greater thanMa 20025.160
OpenGreater thanClose25.430
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Corcept with someone you think should read this too:
  • Are you bullish or bearish on Corcept? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Corcept? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Corcept Therapeutics Incorporated

I send you an email if I find something interesting about Corcept Therapeutics Incorporated.


Comments

How you think about this?

Leave a comment

Stay informed about Corcept Therapeutics Incorporated.

Receive notifications about Corcept Therapeutics Incorporated in your mailbox!